Nitric oxide (NO) plays an important role in the compensatory increase in coronary flow conductance against myocardial ischemia and NO bioavailability is impaired in various diseases. We tested the hypothesis that, when NO production is inhibited, vasoconstrictor signals from the ischemic myocardium are unmasked. We investigated the involvement of endothelin type-A (ET A ) receptors in the transduction of the constrictor signal. To detect coronary vasoactive signals derived from ischemic myocardium, we used a bioassay system in which an isolated rabbit coronary microvessel (detector vessel) was placed on 
INTRODUCTION
During myocardial ischemia, the coronary arterial microvessels relax, resulting in a decrease in coronary resistance as a compensatory defense mechanism. Although ischemic myocardium releases various vasoactive substances (22) , it is uncertain which substances are relevant to the regulation of the coronary microvascular tone.
The research on the cross talk between the myocardium and the coronary microvessels has been hampered because of methodological difficulties. Since the microvascular tone is regulated by many factors besides myocardium-derived factors, such as myogenic tone, shear stress and neurohumoral factors, it is difficult to selectively evaluate the role of myocardium-derived factors. In the case of ischemia, decreases in perfusion pressure and flow rate per se result in changes in myogenic and shear stress-related tone. Furthermore, neurohumoral factors modify the microvascular diameter. To overcome this dilemma, we recently developed a novel bioassay method in which isolated coronary microvessels were placed on the beating heart (30, 31) . This system enables us to control beating hearts and microvessels separately.
Early studies have shown that cardiac nitric oxide (NO) generation is enhanced during myocardial ischemia, and that the released NO participates in the regulation of coronary flow (12, 25) .
And so, it is conceivable that NO plays an important role in mediating the cross talk between ischemic myocardium and coronary resistance vessels. However, it is not certain whether the signals that cause ischemia-induced NO production derive from the myocardium or the vascular lumen.
Because NO bioavailability is impaired in various diseases (10, 27) , it is of interest to determine how the cross talk between the ischemic myocardium and coronary microvessels is modified when NO production is impaired. As some vosoconstrictors such as endothelin-1 (ET-1) (18, 33) are known to be P5 elevated in cardiac ischemia, it is possible that blockade of NO production unmasks microvascular constrictions.
Accordingly, we tested the hypotheses that when NO production is inhibited, the vasoconstriction caused by ischemic myocardium-derived factor is unmasked and that endothelin type-A (ET A ) receptor is responsible for the signal transduction.
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METHODS
In the bioassay method we used for the detection of myocardium-derived vasomotor signals, we combined an isolated microvascular preparation with an in vivo beating heart (31). The present study was approved by the institutional ethical committee for animal experiments and conformed to the Guide for the Care and Use of Laboratoy Animals published by the US National Institute of Health (NIH Publication No.85-23, revised 1996).
Preparation of detector microvessels
Male Japanese white rabbits (n = 38, body weight: 2.16 ± 0.03 kg, 10 to 13 week-old) were anesthetized with pentobarbital (50 mg/kg, i.v.) and heparinized (1000 U, i.v.). After the rabbits were sacrificed by bleeding from the carotid artery, the hearts were quickly excised and immersed in chilled Krebs solution (in mmol/L: NaCl 120.0, KCl 4.7, CaCl 2 2.0, MgSO 4 1.17, NaH 2 PO 4 1.20, calcium disodium EDTA 0.02, NaHCO 3 25.0, Glucose 5.0, adjusted the solution pH to 7.40 by bubbling with 95% O 2 and 5% CO 2 ). A coronary arterial microvessel perfusing the left ventricle (100 to 300 µm) was carefully isolated and used for a detector vessel (DV). One end of the vessel was cannulated to a polyethylene micropipette filled with filtered Krebs solution, the tip of which was tapered (< 100 µm), and tied with a monofilament of silk suture thread (diameter 2 µm). The micropipette was connected to a polyethylene tube and to a pressure reservoir. The other end of the vessel was completely ligated, and the intraluminal pressure was monitored with a strain-gauge transducer (TC0406S01, Baxter) to detect vascular leaks. Vessels with any leakage were not used for further experiments. The DV was incubated in warm (38 ºC) Krebs solution bubbled with 95% O 2 and 5% CO 2 until use.
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Beating-heart preparation
Mongrel dogs of either sex (n = 38, 6.9 ± 0.5 kg) were used and prepared as in our previous studies (1, 31) . Briefly, the dogs were anesthetized with alpha-chloralose (60 mg/kg, Wako Chemicals) and artificially ventilated. The right jugular vein was cannulated for the administration of anesthetics. A catheter was placed in the ascending aorta for measurement of the aortic pressure. A thoracotomy was performed, and the pericardium was cut to expose the heart surface. The left anterior descending coronary artery (LAD) was dissected, and a snare was placed for coronary occlusion.
The heart rate was kept constant at 100 to 120 beats/minute by left atrial pacing after suppression of the sinoatrial node with an injection of formaldehyde. Two 24-guage stainless-steel needles were inserted horizontally (5 to 7 mm apart) into the mid-myocardium of the left ventricle. Both ends of each needle were fixed to a needle holder. This apparatus limits the excessive movement of the heart, thereby keeping the region of interest within the observation field.
Bioassay method
The incubated DV was gently placed on the LAD perfusion area of the beating left ventricle of the dog and pressurized to 60 cm H 2 O to produce intrinsic tone. Only one DV was used for each experiment. The DV and the heart surface were kept moist throughout the experiment by continuous superfusion of Krebs solution (38 ºC) at a rate of 1-1.5 ml/min using infusion pump (model STC-521, Terumo, Tokyo).
For visualization of the DV placed on the beating left ventricles, an intravital microscope system equipped with a floating objective and a CCD camera (IGS, Nikon) was used. This optical system was originally developed in our laboratory for the visualization of epimyocardial coronary P8 microvessels of beating-heart throughout the cardiac cycle (1). The microscope objective was a Leitz model PL-fl (X10; numerical aperture of 0.30). An objective lifter was used to carefully adjust the distance between the objective and vessels, so as not to compress the DV. The distance between the floating objective and the heart surface was approximately 0.5 mm and that space was filled with Krebs solution, which is superfused as described above.
Epi-illumiation with a mercury lamp was applied to obtain the image of the DV. A polarizing filter (IGS, Nikon) was used to minimize reflected light from the surface of the heart. Obtained images were recorded with the digital video recorder (DSR-20, Sony). The spatial resolution of this optical system was 2 µm.
The images of the DV were captured on a PC monitor and the inner diameters were measured with Scion Image (version 4.0.2, Scion). On the monitor screen, one cursor was set on the vessel wall of interest, and another cursor was set on the nearest point of the other side of the vessel wall. Vascular diameters were measured at least three times during the end-diastolic phase.
Experimental protocols
Experiments were performed approximately 1 hour after placing the DV, when all hemodynamic variables and blood gas data had become stable and the intrinsic tone of the DV had developed.
Protocol 1 (Vehicle group, n = 7). After the intrinsic tone of the DV attained stability, the baseline hemodynamic variables were measured and the LAD of the beating heart was occluded. Images of the DV were collected at 2, 3, 5, and 10 minutes after the induction of ischemia. Hemodynamic variables were also collected after10 minute-ischemia. Protocol 5 (ECE-I group, n=4). We superfused FR901533 (100 µmol/L), a selective endothelin converting enzyme inhibitor (ECE-I), to investigate the role of endothelin converting enzyme (ECE) in the ischemia-induced ET release. Twenty minutes after the FR901533, the LAD was occluded and data collection was performed as in Protocol 1.
In each protocol, ischemia of the myocardium on which the DV was placed was confirmed by the dyskinetic wall motion and cyanotic color changes of the heart. At the end of each experiment, sodium nitroprusside (100 µmol/L) was superfused for 5 minutes to confirm the preserved vasodilator capacity.
Measurement of the plasma concentration of ET-1
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In another set of experiments (n=9), we measured the plasma ET levels in the aorta and in the coronary vein draining from the ischemic area to investigate whether myocardial ischemia for 10 minutes enhances the ET release into the vascular lumen. Blood samples (3.0 ml) were collected before and 10 minutes after LAD occlusion and immediately centrifuged at 3000 rpm for 10 minutes at 4 °C. The plasma fraction was stored at -20 °C until analysis. Plasma ET was quantitated with radioimmunoassay. 
Data Analysis
All variables were expressed as the mean ± SEM. The responses of the DV diameters were expressed as the percent change in diameter. When the intrinsic tone of the DV was not observed (baseline diameter > 90 % of the maximal diameter), the vessel was discarded. The maximal diameters were defined as the greatest DV diameter among passive diameter right after the isolation and after 100 µmol/L of sodium nitroprusside at the distending pressure of 60 cm H 2 O. The aortic pressure and vascular diameters were statistically analyzed by using one-way ANOVA for repeated measures and the P11 Student's t -test for paired samples, with Bonferroni correction applied to detect the time point when significant changes occurred. At p < 0.05, the differences were accepted as significant.
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RESULTS
Blood gases and aortic pressure
Blood pH, blood gases and aortic pressure before and after ischemia are shown in the table.
Blood pH and blood gases were kept within the physiological range. There were no differences in the mean aortic pressure between before ischemia and the end of ischemia, in any of the protocols.
Detector vessel responses
The sizes of DV for each protocol were 227 ± 11 µm (Protocol 1), 222 ± 17 µm (Protocol 2), between Protocol 1 and Protocol 2 was statistically significant (p<0.05). These observations indicated that the blockade of NO production unmasked the ischemic myocardium-derived vasoconstrictor signals.
In Protocol 3 (LNNA+BQ-123 group), the combined pretreatment with BQ-123 and LNNA per se did not alter the diameter of the DV (before: 156±13 µm, after: 146±11 µm, NS). Myocardial ischemia did not produce significant diameter changes in the DV (Figure 1-EF, Figure 2 ). These results indicate that the vasoconstriction observed in Protocol 2 was mediated by the activation of ET A receptors in coronary arterial microvessels.
In Protocol 4 (BQ-123 group), the pretreatment with BQ-123 did not change the DV diameter (before: 139±14 µm, after: 150±15 µm). Myocardial ischemia produced significant dilation of DV, and the magnitude of the dilation was greater than that in the vehicle group (Fig 1-GH, Figure 2 ). BQ-123 induced an enhancement of the dilator responses indicating that myocardial ischemia activates the vasoconstrictor signal mediated by ET even in the absence LNNA.
In Protocol 5 (ECE-I group), FR901533 did not change the DV diameter (before: 130±7 µm, after: 147±14 µm). Myocardial ischemia produced significant dilation of DV but the magnitude of the dilation was not different from that of the vehicle group (percent diameter changes, 2 min: 8 ± 2 %, 3 min: 10 ± 1 %, 5 min: 12 ± 2 %, 10 min: 13 ± 2%).
There were no differences in the dilator responses of DV to sodium nitroprusside (100 µmol/L) among the five protocols. Figure 3 shows the group data of plasma ET measurements before and after 10 minute-ischemia. In neither the coronary vein nor aorta, did the plasma ET-1 level change. The P14 arteriovenous difference in the plasma ET-1 concentration, which represents ET-1 production in the coronary circulation, did not significantly increase by myocardial ischemia ( Figure 3C ).
Plasma ET-1
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DISCUSSION
In the present study, we found the following: 1) ischemic myocardium releases the transferable vasodilator signal, 2) when nitric oxide release is impaired, the ischemic myocardium-derived vasoactive signal which produces coronary microvascular constriction is unmasked, 3) the vasoconstrictor signal is mediated by ET A receptors, 4) ET A receptor blocker enhances the ischemia-induced coronary microvascular dilation, suggesting that ischemic myocardium simultaneously releases signals activating nitric oxide release and ones activating endothelin release, 5) ECE-I does not enhance the ischemia-induced dilation, suggesting that endothelin released during acute myocardial ischemia derives from mature endothelin pools rather than de novo synthesis.
Methodological consideration
Our primary interest was to detect the vasomotor signals derived from ischemic myocardium.
In our bioassay system, the distending pressure (60 cm H 2 O) and flow state (stop flow) of the DV were kept constant throughout the experiment irrespective of the myocardial condition. Therefore, we did not have to take myogenic factors and shear stress into account for the ischemia-induced microvascular responses. Furthermore, since the DV were separated from the blood stream and nervous controls, the DV responses by myocardial ischemia were unlikely to be influenced by systemic neurohumoral changes. Thus, we can specifically focus on the cross talk between the myocardium and the coronary microvessels. The magnitude of the dilation of the DV by myocardial ischemia was almost identical to that in our previous observation (30, 31) , confirming the reproducibility of our method.
The diameters of the DV were approximately 200 µm at their maximal relaxations and they were 150-200 µm when intrinsic tone developed. It could be argued whether or not microvessels of this P16 size contribute to vascular resistance. Since Chilian et al. (5) have previously shown that 20 percent of vascular resistance resides in microvessels greater than 200 µm in diameter, it is reasonable to consider that the DV we used are vascular segments which bear significant coronary resistance.
To keep the heart surface moist and warm, we superfused warm Krebs solution throughout the experiment at the rate of 1-1.5 ml/min. Accordingly, the space between the floating objective and heart surface (0.5 mm apart) was always filled with the solution. The Krebs solution remaining in that space probably diluted the signal from the myocardium. Therefore, it is possible that the magnitude of the vasomotor signals evaluated in our bioassay method was underestimated to some extent. In other words, the cross talk between the myocardium and the microvessel was very intense in terms of the vasomotor responses.
Vasodilator signals derived from ischemic myocardium
There have been some earlier studies suggesting that NO release is enhanced during myocardial ischemia (12, 25) . The present results are in line with those data, and we elucidated that the signal which stimulates NO production originates from the ischemic myocardium.
LNNA abolished the dilator signal from ischemic myocardium, demonstrating that the L-arginine-NO pathway is the main signaling system that mediates microvascular relaxation during myocardial ischemia. However, there could be some other possible mediators such as the activation of ATP-sensitive K channels (K ATP channels) and the release of adenosine (14) . Vessel size-specificity of vasodilatory mechanisms may explain this issue. Coronary microvascular responses to various interventions are strikingly heterogeneous according to the vessel sizes (14) . We used relatively large microvessels (~ 200 µm), and in this size class of microvessels, L-arginine-NO pathway is a dominant P17 mechanism while adenosine and K ATP channel activation is dominant in smaller microvessels (15, 16, 19) .
We previously reported that vasodilator signals released from ischemic myocardium are mediated by pertussis toxin-sensitive G proteins (G PTX ) located in the vascular wall (31) and that microvascular G PTX is functionally linked with the NO pathway in coronary microvessels greater than 130 µm in diameter (17) . In addition, G PTX is known to exist in vascular endothelial cells (6) . On the basis of those observations, it is conceivable that myocardial vasodilator signals act on the endothelial G PTX of DV which activate endothelial NO synthase leading to NO production. We cannot draw conclusions about the mediator responsible for the NO release during myocardial ischemia from our studies, but we speculate that myocardial and/or interstitial acidosis is one plausible mediator. Kitakaze et al (13) showed that cellular acidosis modulates the production of endogenous NO in canine ischemic myocardium and the possibility that proton activates G PTX was shown by Ishizaka et al (11) .
Vasoconstrictor signals derived from ischemic myocardium
When vessel diameters decrease in response to a decrease in the perfusion pressure, there could be two possibilities, passive collapse or active contraction. The present studies have clearly shown that when NO production is impaired, myocardial ischemia produces active constriction by the stimulation of ET A receptors without apparent elevation of plasma ET-1. The plasma ET-1 level in the present experiments was 5-7 pg/ml (~2 pmol/L) and there was no increase in either the aorta or coronary vein in the ischemic region, demonstrating that no systemic or local increase in intravascular ET resulted from the 10 minute-ischemia. Although an elevation of plasma ET has been shown in myocardial ischemia in both human (24) and in animals (2, 35) , an ischemic period of more than one hour is required for the increase. Previous data from our group and others have
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shown that the threshold concentration of ET for coronary microvascular constriction is 10 -100 pmol/L (23, 36) . Accordingly, the plasma ET in the vascular lumen during the 10 minute-ischemia was much lower than the vasoactive concentration.
ECE in the heart is localized to the vascular endothelial cells and endocardial endothelial cells but not to the cardiac myocytes in animals and human (7, 32) . And so it is unlikely that ischemic myocardium itself released ET in the present experiment. Endocardial endothelial cells are also an unlikely source of ET, which can account for the DV constriction, because the plasma ET was not increased by ischemia. It is conceivable that some signals derived from ischemic myocardium activate the ET release from vascular endothelium. Winegrad et al (37) have demonstrated that isolated cardiac myocytes do not release endothelin but do release angiotensin I leading to endothelin release from vascular endothelium.
Since ET-mediated constriction of the DV took place without an increase in plasma ET-1, it is likely that the ET released from the microvascular endothelium constricts the microvascular smooth muscle in a paracrine manner. Wagner et al (34) have demonstrated that the secretion of ET is polarized, that is, the majority of ET is released into the basolateral compartment (abluminal side). These observations indicate that ET is a local paracrine regulator of vascular tone. Wang et al . (35) have shown that the major portion of ET released during ischemia/reperfusion is trapped within the heart with only small amounts released into the vascular lumen.
There are two distinct secretory pathways in the process of ET-1 release in the coronary vasculature (28, 29) . One is a constitutive pathway, which is modulated at the level of protein synthesis and involves the basal release of ET-1, and the other is a regulated pathway that involves rapid, stimulated degranulation of ET-1-contained storage granules. In the latter pathway, ET is quickly released P19 in response to various stimulations (8, 21) , and exerts the biological effects. The storage granules have been detected in endothelial cells, and big ET-1 and ECE have been found to co-localize with the storage granules located beneath the plasma membrane (29) . Since the vasoconstriction we observed was an immediate response, ET is likely to be released in the regulated manner.
It is possible that the myocardial ischemia stimulates the release of a factor(s) that stimulate NO and ET-1 release simultaneously. Another possibility is that NO inhibits the ET release and that the inhibition of NO accelerates the release. In the present studies, BQ-123 augmented the ischemia-induced DV dilation even in the absence of NO blockade. Accordingly, ischemic myocardium is likely to release signals that stimulate NO production and that stimulate ET release simultaneously. As ECE-I did not significantly enhance the DV dilation, the endothelin release in response to acute ischemia may derive from mature endothelin pools.
Effect of NO on endothelin system
At first, NO has been known to inhibit the production of ET in cultured endothelial cells (4) and in intact vessels (3) . However, the vasoconstrictions we observed were immediate responses, and so the released ET must be the stored type, not produced de novo. To our knowledge, there is no evidence that NO inhibits ET release from stored granules.
The impact of NO on ET signal transduction has been investigated in earlier studies and it has been shown that the suppression of NO production generally unmasks or magnifies ET-dependent effects (20) , indicating that NO plays a role as a breaking mechanism for the ET action. Goligorsky et al (9) have shown that NO plays a role in the physiological termination of ET-1 signaling at the receptor level (displacement of bound ET-1 from its receptor) and at the post-receptor level (intracellular calcium P20 mobilization). These mechanisms may be involved in the phenomenon by which NO blockade unmasks the DV constriction.
Clinical implication
NO bioavailability is limited in various diseases such as hypertension (27) , hypercholesterolemia (27) , diabetes mellitus (10) and atherosclerosis (26) . It is plausible that under such diseased conditions, acute myocardial ischemia results in a greater decrease in coronary flow. Very recently, we demonstrated that the cross talk between coronary microvessels and the ischemic myocardium is impaired in hypercholesterolemia (30) . Accordingly, ET A receptor blocker may be beneficial for the amelioration of decreased coronary microvascular blood flow and ischemic myocardial damage, especially in such diseased conditions. P21
